Semin Thromb Hemost 2006; 32(7): 694-699
DOI: 10.1055/s-2006-951297
Copyright © 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Cancer and Venous Thromboembolism

Andrea Piccioli1 , Anna Falanga2 , Ugo Baccaglini3 , Marina Marchetti2 , Paolo Prandoni1
  • 1Department of Medical and Surgical Sciences, University of Padua, Italy
  • 2Division of Hematology, Department of Hematology-Oncology, Ospedali Riuniti di Bergamo, Bergamo, Italy
  • 3Department of Day Surgery, University of Padua, Italy
Further Information

Publication History

Publication Date:
06 October 2006 (online)


The evidence of the important two-way clinical correlation between cancer and venous thromboembolism (VTE) dates back to Trousseau's time. Over time it has been established that cancer patients not only exhibit a higher risk of developing VTE when compared with noncancer patients, but also that VTE, especially in its idiopathic presentation, sometimes acts as an epiphenomenon of a hidden cancer, offering possible chances for anticipated diagnosis of the pathology. Research has contributed greatly to the progression of this field through the identification of VTE risk factors in this setting, and through the assessment of the most adequate thromboprophylaxis and treatment modalities as well as secondary prophylaxis management. Anticoagulant drugs appear to be an attractive strategy in cancer treatment because there is growing evidence for their possible benefits in terms of cancer prognosis and patient survival.


  • 1 Trousseau A. Phlegmasia alba dolens. In: Clinique Medical de l'Hotel Dieu de Paris. London; The New Sydenham Society 1865: 94-96
  • 2 Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism.  Lancet Oncol. 2005;  6 401-410
  • 3 Falanga A, Barbui T, Rickles F R, Levine M N. Guidelines for clotting studies in cancer patients.  Thromb Haemost. 1993;  70 540-542
  • 4 Falanga A, Donati M B. Pathogenesis of thrombosis in patients with malignancy.  Int J Hematol. 2001;  73 137-144
  • 5 Gale A J, Gordon S G. Update on tumor cell procoagulant factors.  Acta Haematol. 2001;  106 25-32
  • 6 Otten H M, Prins M H. Venous thromboembolism and occult malignancy.  Thromb Res. 2001;  102 V187-V194
  • 7 Blom J W, Doggen C J, Osanto S, Rosendaal F R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis.  JAMA. 2005;  293 715-722
  • 8 Piccioli A, Prandoni P, Ewenstein B M, Goldhaber S Z. Cancer and venous thromboembolism.  Am Heart J. 1996;  132 850-855
  • 9 Shen V S, Pollak E W. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified?.  South Med J. 1980;  73 841-843
  • 10 Prandoni P, Piccioli A, Girolami A. Cancer and venous thromboembolism: an overview.  Haematologica. 1999;  84 437-445
  • 11 Huber O, Bounameaux H, Borst F, Rohner A. Postoperative pulmonary embolism after hospital discharge: an underestimated risk.  Arch Surg. 1992;  127 310-313
  • 12 Bergqvist D, Agnelli G, Cohen A T et al.. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.  N Engl J Med. 2002;  346 975-980
  • 13 Levine M N. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy.  Thromb Haemost. 1997;  78 133-136
  • 14 Goodnough L T, Saito A, Manni A et al.. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen: a study of 159 patients.  Cancer. 1984;  54 1264-1268
  • 15 Otten H MMB, Mathijssen J, ten Cate H et al.. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon.  Arch Intern Med. 2004;  164 190-194
  • 16 Prichard K I, Paterson A H, Paul N A et al.. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer.  J Clin Oncol. 1996;  14 2731-2737
  • 17 Deitcher S R, Gemes M PV. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma.  Cancer. 2004;  101 439-449
  • 18 Goldhaber S Z. Tamoxifen: preventing breast cancer and placing the risk of deep vein thrombosis in perspective.  Circulation. 2005;  111 539-541
  • 19 Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients.  J Clin Oncol. 2003;  21 3665-3675
  • 20 Bern M M, Lokich J J, Wallach S R et al.. Very low dose of warfarin can prevent thrombosis in central venous catheters: a prospective trial.  Ann Intern Med. 1990;  112 423-428
  • 21 Monreal M, Alastrue A, Rull M et al.. Upper extremity deep vein thrombosis in cancer patients with venous access devices prophylaxis with a low molecular weight heparin (Fragmin).  Thromb Haemost. 1996;  75 251-253
  • 22 Levine M N, Lee A Y, Kakkar A K. From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer.  J Thromb Haemost. 2003;  1 1456-1463
  • 23 Geerts W H, Pineo G F, Heith J A et al.. Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy.  Chest. 2004;  126 338S-400S
  • 24 Bergqvist D, Burmark U S, Flordal P A et al.. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 anti Xa IU in 2070 patients.  Br J Surg. 1995;  82 496-501
  • 25 Enoxacan Study Group . Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment.  Br J Surg. 1997;  84 1099-1103
  • 26 Rasmussen M S, Jorgensen L N, Wille-Jorgensen J P et al.. Prolonged prophylaxis with low molecular weight heparin (Dalteparin) after major abdominal surgery: the FAME study. In: Programs and Abstracts of the XIX Congress of the International Society of Thrombosis and Haemostasis July 12-18, 2003 Birmingham, United Kingdom (abst);
  • 27 Nurmohamed M T, van Riel A M, Henkens C M et al.. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery.  Thromb Haemost. 1996;  75 233-238
  • 28 Agnelli G, Piovella F, Buoncristiani P et al.. Enoxaparin plus compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery.  N Engl J Med. 1998;  339 80-85
  • 29 Levine M, Hirsh J, Gent M et al.. Double-blind randomized trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer.  Lancet. 1994;  343 886-889
  • 30 Büller H R, Agnelli G, Hull R D et al.. Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP Conference on antithrombotic and thrombolytic therapy.  Chest. 2004;  126(suppl) 401S-428S
  • 31 Prandoni P, Lensing A WA, Cogo A et al.. The long-term clinical coarse of acute deep vein thrombosis.  Ann Intern Med. 1996;  125 1-7
  • 32 Heit J A, Mohr D N, Silverstein M D et al.. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study.  Arch Intern Med. 2000;  160 761-768
  • 33 Prandoni P, Lensing A WA, Piccioli A et al.. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thromboembolism.  Blood. 2002;  100 3484-3488
  • 34 Lee A Y, Levine M N, Baker R I et al.. Low-molecular-weight heparin versus a coumarin for the prevention of venous thromboembolism in patients with cancer.  N Engl J Med. 2003;  349 146-153
  • 35 Meyer G, Marjanovic Z, Valcke J et al.. Comparison of low-molecular weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.  Arch Intern Med. 2002;  162 1729-1735
  • 36 Falanga A, Piccioli A. Effect of anticoagulant drugs in cancer.  Curr Opin Pulm Med. 2005;  11 403-407
  • 37 Kakkar A K, Levine M N, Kadziola Z et al.. Low-molecular-weight heparin therapy with dalteparin and survival in advanced cancer: the Fragmin advanced malignancy outcome study.  J Clin Oncol. 2004;  22 1944-1948
  • 38 Klerk C PW, Smorenburg S M, Otten H YM et al.. The effect of low-molecular-weight heparin on survival in patients with advanced malignancy.  J Clin Oncol. 2005;  23 2130-2135
  • 39 Altinbas M, Coskun H S, Er O et al.. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer.  J Thromb Haemost. 2004;  2 1266-1271
  • 40 Sorensen H T, Mellemkjaer L, Steffensen H et al.. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism.  N Engl J Med. 1998;  338 1169-1173
  • 41 Baron J A, Gridley G, Weiderpass E et al.. Venous thromboembolism and cancer.  Lancet. 1998;  351 1077-1080
  • 42 Murchison J T, Wylie L, Stockton D L. Excess risk of cancer in patients with primary venous thromboembolism: a national population-based cohort study.  Br J Cancer. 2004;  91 92-95
  • 43 White R H, Chew H K, Zhou H et al.. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults.  Arch Inter Med. 2005;  65 1782-1787
  • 44 Sorensen H T, Mellemkjare L, Olsen J H, Baron J A. Prognosis of cancers associated with venous thromboembolism.  N Engl J Med. 2000;  343 1846-1850
  • 45 Monreal M, Lensing A WA, Prins M H et al.. Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism.  J Thromb Haemost. 2004;  2 876-881
  • 46 Piccioli A, Lensing A WA, Prins M H et al.. Extensive screening for occult malignant disease in idiopathic venous thromboembolism.  J Thromb Haemost. 2004;  2 884-889

Andrea PiccioliM.D. 

Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, University of Padua

Via Ospedale Civile 105, 35128 Padua, Italy